Inhibikase executives and key opinion leaders highlight recently presented Phase 1 and Phase 1b data for IkT-148009 for the treatment of #ParkinsonsDisease, provide an overview of the upcoming Phase 2 program, and highlight the current unmet need and competitive landscape in Parkinson's disease during Inhibikase’s Virtual KOL Event.
- Milton H Werner, PhD – Inhibikase President & CEO
- C. Warren Olanow, MD – Inhibikase Interim CMO, Clintrex Research Corporation CEO, Professor & Chair Emeritus, Department of Neurology and Professor, Department of Neuroscience, Mount Sinai School of Medicine
- Werner Poewe, MD - Professor of Neurology and Director of the Department of Neurology at Innsbruck Medical University in Innsbruck, Austria
- Robert F. Hauser, MD - Director of Parkinson's & Movement Disorder Center and Professor, College of Medicine Neurology at University of South Florida.